This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Sotio a.s. Identifier:
First received: April 4, 2014
Last updated: July 31, 2017
Last verified: January 2016
The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy (carboplatin and gemcitabine as second line chemotherapy) may result in prolongation of progression free survival (PFS).

Condition Intervention Phase
Ovarian Neoplasms Ovarian Cancer (OvCa) Ovarian Epithelial Cancer Biological: DCVAC/OvCa in parallel with chemotherapy Drug: Standard of Care Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial DCVAC/OvCa Added to Standard Chemotherapy in Women With Relapsed Platinum Sensitive Epithelial Ovarian Carcinoma

Resource links provided by NLM:

Further study details as provided by Sotio a.s.:

Primary Outcome Measures:
  • Determine median progression free survival [ Time Frame: 72 Week ]

Secondary Outcome Measures:
  • Overall survival (all causes) [ Time Frame: 56, 64, 72 weeks ]
  • Objective Response Rate [ Time Frame: 8, 16, 24, 32, 40, 48, 56. 64. 72 weeks ]
  • Biological Progression Free Interval [ Time Frame: 6, 12, 18, 24, 36, 42, 48, 56, 64, 72 weeks ]
  • Immunological Response [ Time Frame: 24, 48, 72 weeks ]
  • Frequency of adverse events [ Time Frame: 8, 16, 24, 32, 40, 48, 56. 64. 72 weeks ]

Estimated Enrollment: 60
Study Start Date: November 2013
Estimated Study Completion Date: November 2017
Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: DCVAC/OvCa in parallel with chemotherapy
Combination therapy with DCVAC/OvCa and Standard of Care
Biological: DCVAC/OvCa in parallel with chemotherapy
DCVAC/OvCa is the experimental therapy added on to Carboplatin and Gemcitabine
Other Names:
  • DCVAC/OvCa
  • carboplatin and gemcitabine
Active Comparator: Standard of Care
Standard of Care carboplatin and gemcitabine
Drug: Standard of Care
Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy
Other Name: Carboplatin and Gemcitabine

Detailed Description:
The purpose of this study is to determine whether DCVAC/OvCa added to Standard of Care chemotherapy (carboplatin and gemcitabine as second line chemotherapy) may result in prolongation of progression free survival (PFS).

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Females 18 years old and older
  • Patients with histologically confirmed, International Federation of Gynecology and Obstetrics (FIGO) stage III or IV epithelial ovarian, primary peritoneal or fallopian tube carcinoma (serous, endometrioid or mucinous), who had complete remission after first line platinum (Pt)-based chemotherapy and are selected to receive second line Standard of Care chemotherapy
  • Radiologically confirmed relapse after >6 months of remission (Platinum-sensitive patients), found up to 4 weeks prior study entry.
  • The patient must have at least one measureable target lesion as defined by the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria to be eligible for enrolment in the study

Exclusion Criteria:

  • FIGO I,II epithelial ovarian cancer
  • FIGO III, IV clear cells epithelial ovarian cancer
  • Non-epithelial ovarian cancer
  • Borderline tumors (tumors of low malignant potential)
  • Prior or current systemic anti-cancer therapy for ovarian cancer [for example chemotherapy, monoclonal antibody therapy , tyrosine kinase inhibitor therapy, vascular endothelial growth factor (VEGF) therapy or hormonal therapy] except first line Platinum-based chemotherapy (with or without bevacizumab)
  • Previous radiotherapy to the abdomen and pelvis
  • Malignancy other than epithelial ovarian cancer, except those that have been in clinical remission (CR) for a minimum of 3 years, and except carcinoma in-situ of the cervix or non-melanoma skin carcinomas
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02107950

Brno, Czechia, 625 00
Brno, Czechia, 656 53
Ceske Budejovice, Czechia, 370 01
Hradec Králové, Czechia, 500 05
Nový Jičín, Czechia, 741 01
Olomouc, Czechia, 755 20
Ostrava, Czechia, 708 52
Prague, Czechia, 128 08
Praha 5, Czechia, 150 06
Cologne, Germany, 50931
Dresden, Germany, 01307
Erlangen, Germany, 91 054
Bialystok, Poland, 15-276
Krakow, Poland, 31-501
Lublin, Poland, 20-081
Poznan, Poland, 60-569
Sponsors and Collaborators
Sotio a.s.
Study Director: Ales Horacek Accord Research
  More Information

Responsible Party: Sotio a.s. Identifier: NCT02107950     History of Changes
Other Study ID Numbers: SOV02
2013-001323-38 ( EudraCT Number )
Study First Received: April 4, 2014
Last Updated: July 31, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: will be posted to EMA website
Supporting Materials: Study Protocol
Clinical Study Report (CSR)
Time Frame: estimate end of 2018

Keywords provided by Sotio a.s.:
Platinum Sensitive

Additional relevant MeSH terms:
Ovarian Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Immune System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on September 21, 2017